No Benefit of High Dose Methotrexate (HD-MTX) in Intermediate Risk Childhood Acute Lymphoblastic Leukemia (ALL): Results of 2 Randomised Multicenter Trials in Russia

被引：0
|
作者：
Karachunskiy, A. [1 ]
Ponomareva, N. [2 ]
Roumiantseva, J. [1 ]
Aleynikova, O. [3 ]
Arakaev, O. [4 ]
Litvinov, D. [1 ]
Karelin, A. [1 ]
Boychenko, E. [5 ]
Sharapova, G. [6 ]
Lagoyko, S. [1 ]
Bydanov, O. [3 ]
Henze, G. [7 ]
机构：
[1] Fed Res Ctr Paediat Haematol Oncol & Immunol, Inst Oncol Radiol & Nucl Med, Moscow, Russia
[2] Russian Childrens Clin Hosp, Dept Haematol, Moscow, Russia
[3] Republ Clin Res Ctr Paediat Haematol Oncol & Immu, Dept Haematol Oncol, Minsk, BELARUS
[4] Reg Childrens Hosp, Paediat Oncohematol Ctr, Ekaterinburg, Russia
[5] St Petersburg Municipal Children Hosp 1, Dept Haematol, St Petersburg, Russia
[6] Reg Childrens Clin Hosp, Dept Haematol, Nizhnevartovsk, Russia
[7] Charite Univ Med Berlin, Dept Paediat Oncol Haematol, Berlin, Germany
来源：
PEDIATRIC BLOOD & CANCER | 2016年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-089
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [31] Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia
    Pession, A
    Valsecchi, MG
    Masera, G
    Kamps, WA
    Magyarosy, E
    Rizzari, C
    van Wering, ER
    Lo Nigro, L
    van der Does, A
    Locatelli, F
    Basso, G
    Aricò, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 7161 - 7167
  • [32] Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434
    Winter, Stuart S.
    Devidas, Meenakshi
    Chen, Si
    Asselin, Barbara
    Carroll, William L.
    Wood, Brent L.
    Esiashvili, Natia
    Nikki, Briegel J.
    Hayashi, Robert J.
    Loh, Mignon L.
    Carroll, Andrew J.
    Heerema, Nyla A.
    Raetz, Elizabeth
    Winick, Naomi J.
    Hunger, Stephen P.
    Dunsmore, Kimberly P.
    BLOOD, 2015, 126 (23)
  • [33] Consolidation therapy with intermediate dose methotrexate (IDM) alone, or IDM and L-asparaginase (ASP), or IDM and cytosine arabinoside (ARAC) in standard risk acute lymphoblastic leukemia (ALL) of childhood: A pediatric oncology group (POG) study.
    Harris, MB
    Land, VJ
    Shuster, JJ
    Borowitz, MJ
    Behm, FG
    Pullen, DJ
    BLOOD, 1996, 88 (10) : 2661 - 2661
  • [34] RETROSPECTIVE ANALYSIS OF LATE INTENSIFICATION THERAPY WITH HIGH-DOSE METHOTREXATE FOR STANDARD-RISK ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD (CCLSG-S811 STUDY)
    KOIZUMI, S
    FUJIMOTO, T
    SASAKI, K
    TAKEDA, T
    UTSUMI, J
    MIMAYA, J
    OHTA, S
    NINOMIYA, T
    TAKAUE, Y
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1991, 54 (04) : 307 - 313
  • [35] Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study
    Schmiegelow, Kjeld
    Al-Modhwahi, Ibrahim
    Andersen, Mette Klarskov
    Behrendtz, Mikael
    Forestier, Erik
    Hasle, Henrik
    Heyman, Mats
    Kristinsson, Jon
    Nersting, Jacob
    Nygaard, Randi
    Svendsen, Anne Louise
    Vettenranta, Kim
    Weinshilboum, Richard
    BLOOD, 2009, 113 (24) : 6077 - 6084
  • [36] Treatment results of high-risk defined by NCI criteria childhood acute lymphoblastic leukemia in AIEOP-ALL studies over two decades.
    Aricò, M
    Conter, V
    Valsecchi, MG
    Rizzari, C
    Barisone, E
    Messina, C
    Lo Nigro, L
    Pinta, MF
    De Rossi, G
    Pession, A
    Testi, AM
    Santoro, N
    Di Tullio, MT
    Micalizzi, C
    Favre, C
    Lippi, A
    Rondelli, R
    Silvestri, D
    Biondi, A
    Basso, G
    Masera, G
    BLOOD, 2000, 96 (11) : 464A - 465A
  • [37] The use of lenograstim (G-CSF) to increase the chemotherapy dose-intensity (CDI):: A randomized trial in very high risk childhood acute lymphoblastic leukemia (ALL).
    Michel, G
    Landman, J
    Leblanc, T
    Bordigoni, P
    Lamagnère, JP
    Legall, E
    Deméocq, F
    Pérel, Y
    Pautard, B
    Vannier, JP
    Couillaud, G
    Baruchel, A
    Leverger, G
    Schaison, G
    BLOOD, 1998, 92 (10) : 399A - 399A
  • [38] COMPARISON OF 2 SCHEDULES OF INTERMEDIATE-DOSE METHOTREXATE AND CYTARABINE CONSOLIDATION THERAPY FOR CHILDHOOD B-PRECURSOR CELL ACUTE LYMPHOBLASTIC-LEUKEMIA - A PEDIATRIC-ONCOLOGY-GROUP STUDY
    LAND, VJ
    SHUSTER, JJ
    CRIST, WM
    RAVINDRANATH, Y
    HARRIS, MB
    KRANCE, RA
    PINKEL, D
    PULLEN, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) : 1939 - 1945
  • [39] Oral Methotrexate/6-mercaptopurine may be Superior to a Multidrug LSA2L2 Maintenance Therapy for Higher Risk Childhood Acute Lymphoblastic Leukemia Results From the NOPHO ALL-92 Study
    Schmiegelow, Kjeld
    Heyman, Mats
    Kristinsson, Jon
    Mogensen, Ulla B.
    Rosthoj, Susanne
    Vettenranta, Kim
    Wesenberg, Finn
    Saarinen-Pihkala, Ulla
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2009, 31 (06) : 385 - 392
  • [40] Outcome of allogeneic BMT in high-risk childhood T-Cell acute lymphoblastic leukemia (HR-T-ALL) compared to treatment with chemotherapy alone: results from trials ALL-BFM 90 and ALL-BFM 95
    Schrauder, A
    Reiter, A
    Zimmermann, M
    Klingebiel, T
    Mann, G
    Welte, K
    Schrappe, M
    BONE MARROW TRANSPLANTATION, 2002, 29 : S7 - S8
12345